The Greek Association of Alzheimer’s Disease in cooperation with the Angelopoulos Foundation, the ΑSPAD and ΕνΝΟΗΣΗΣ research programs of the AUT and the PanHellenic Institute of Neurodegenerative Diseases organized a scientific conference under the title: “Moral Dilemmas and New Technologies in the treatment of Dementia” that took place in the KEDEA Hall of the AUT wich took place on 19-20 September 2014.

The conference objective was to record the latest developments in the field of Dementia by bringing in direct contact scientists from across the world and consequently allow the exchange of experience for the update of the health care professionals along with all the other concerned groups for the very serious medically but also socially subject of Dementia.

ΙΑSIS PHARMA warmly supported this effort and there was a strong interest by the medical community for three of the most important neurological products of the company, namely Referan®, Venalxin® and Gabantin®.

Referan®, aniracetam (in the form of tabs and sachets), is an original product αποτελεί indicated from mild Dementia that improves the symptoms of brain atrophy in the elderly that are expressed as a cognitive deficit. Venlaxin, venlafaxine (anti-depressive) is a hybrid product in a novel pharmaceutical form (prolonged tabs) that allows the gradual release of venlafaxine in the human body, while the size of the tablet increases patient compliance. Gabantin, gabapentin, is the first gabapentin generic launched in Greece and is indicated as an adjunctive treatment for epileptic seizures and as a treatment for peripheral neuropathic pain.